We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » US FDA’s Safe Use Initiative May Increase REMS
US FDA’s Safe Use Initiative May Increase REMS
November 16, 2009
Drugmakers may see a rise in the number of required risk evaluation and mitigation strategies (REMS) required by the U.S. Food and Drug Administration
(FDA) under its Safe Use Initiative launched this month.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor